50 related articles for article (PubMed ID: 25626861)
1. Outcomes from hematopoietic stem cell transplantation following treosulfan-based conditioning: A clinical and pharmacokinetic analysis.
Rosser SPA; Brewer A; Gabriel M; Wong M; Chung J; McLachlan AJ; Nath CE; Keogh SJ; Shaw PJ
Pediatr Transplant; 2024 Jun; 28(4):e14780. PubMed ID: 38766999
[TBL] [Abstract][Full Text] [Related]
2. Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm.
Huang X; Wang S; Xu Y; Mei C; Han Q; Wu X; Du F; Ren Y; Jin J; Tong H; Qian J
Ann Hematol; 2024 Jun; 103(6):2165-2168. PubMed ID: 38584216
[TBL] [Abstract][Full Text] [Related]
3. Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial.
Sykora KW; Beier R; Schulz A; Cesaro S; Greil J; Gozdzik J; Sedlacek P; Bader P; Schulte J; Zecca M; Locatelli F; Gruhn B; Reinhardt D; Styczynski J; Piras S; Fagioli F; Bonanomi S; Caniglia M; Li X; Baumgart J; Kehne J; Mielcarek-Siedziuk M; Kalwak K
Bone Marrow Transplant; 2024 Jan; 59(1):107-116. PubMed ID: 37925531
[TBL] [Abstract][Full Text] [Related]
4. Busulfan-Based and Treosulfan-Based Myeloablative Conditioning for Allogeneic Transplantation in Children with Thalassemia Major: a Single-Center Experience From Southern Turkey.
Aygüneş U; Karagun BS; Ay Tuncel D; Sasmaz HI; Antmen B
Exp Clin Transplant; 2023 Nov; 21(11):883-892. PubMed ID: 38140932
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Complications after Allogeneic Hematopoietic Stem Cell Transplantation with Treosulfan- or Busulfan-Based Conditioning in Pediatric Patients with Acute Leukemia or Myelodysplastic Syndrome: Results of an Associazione Italiana Ematologia Oncologia Pediatrica Retrospective Study.
Saglio F; Pagliara D; Zecca M; Balduzzi A; Cattoni A; Prete A; Tambaro FP; Faraci M; Calore E; Locatelli F; Fagioli F;
Transplant Cell Ther; 2024 Apr; 30(4):433.e1-433.e10. PubMed ID: 38176654
[TBL] [Abstract][Full Text] [Related]
6. Treosulfan Exposure Predicts Thalassemia-Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation.
Pai AA; Mohanan E; Panetta JC; Kulkarni UP; Illangeswaran RSS; Balakrishnan B; Jayaraman A; Edison ES; Lakshmi KM; Devasia AJ; Fouzia NA; Korula A; Abraham A; George B; Srivastava A; Mathews V; Standing JF; Balasubramanian P
Clin Pharmacol Ther; 2024 Jan; 115(1):116-125. PubMed ID: 37846495
[TBL] [Abstract][Full Text] [Related]
7. If we do not count it, it does not count: ethnicity in allogeneic haemopoietic stem cell transplant in Australia.
McErlean G; Bajel A; Bhattacharyya A; Brown N; De Abreu Lourenco R; Greenwood M; Kerridge I; Kim N; Kliman D; Maneze D; O'Brien T; Szer J; Twist I
Intern Med J; 2023 Dec; 53(12):2155-2158. PubMed ID: 37814833
[No Abstract] [Full Text] [Related]
8. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation in solid organ transplant recipients: a retrospective, multicenter study of the EBMT.
Basak GW; Wiktor-Jedrzejczak W; Labopin M; Schoemans H; Ljungman P; Kobbe G; Beguin Y; Lang P; Koenecke C; Sykora KW; Te Boome L; van Biezen A; van der Werf S; Mohty M; de Witte T; Marsh J; Dreger P; Kröger N; Duarte R; Ruutu T
Am J Transplant; 2015 Mar; 15(3):705-14. PubMed ID: 25648262
[TBL] [Abstract][Full Text] [Related]
10. Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning.
Jaiswal SR; Chakrabarti A; Chatterjee S; Bhargava S; Ray K; O'Donnell P; Chakrabarti S
Biol Blood Marrow Transplant; 2016 Mar; 22(3):499-504. PubMed ID: 26612281
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.
Oh DH; Chua N; Street L; Stewart DA
Leuk Lymphoma; 2016; 57(1):28-33. PubMed ID: 25747968
[TBL] [Abstract][Full Text] [Related]
12. Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies.
Kalwak K; Mielcarek M; Patrick K; Styczynski J; Bader P; Corbacioglu S; Burkhardt B; Sykora KW; Drabko K; Gozdzik J; Fagioli F; Greil J; Gruhn B; Beier R; Locatelli F; Müller I; Schlegel PG; Sedlacek P; Stachel KD; Hemmelmann C; Möller AK; Baumgart J; Vora A
Bone Marrow Transplant; 2020 Oct; 55(10):1996-2007. PubMed ID: 32203268
[TBL] [Abstract][Full Text] [Related]
13. Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT.
Saraceni F; Labopin M; Raiola AM; Blaise D; Reményi P; Sorà F; Pavlu J; Bramanti S; Busca A; Berceanu A; Battipaglia G; Visani G; Sociè G; Bug G; Micò C; La Nasa G; Musso M; Olivieri A; Spyridonidis A; Savani B; Ciceri F; Nagler A; Mohty M
Hemasphere; 2023 Oct; 7(10):e952. PubMed ID: 37746158
[TBL] [Abstract][Full Text] [Related]
14. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
Lüftinger R; Zubarovskaya N; Galimard JE; Cseh A; Salzer E; Locatelli F; Algeri M; Yesilipek A; de la Fuente J; Isgrò A; Alseraihy A; Angelucci E; Smiers FJ; La La Nasa G; Zecca M; Fisgin T; Unal E; Kleinschmidt K; Peters C; Lankester A; Corbacioglu S;
Ann Hematol; 2022 Mar; 101(3):655-665. PubMed ID: 34999929
[TBL] [Abstract][Full Text] [Related]
15. Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Baronciani D; Depau C; Targhetta C; Derudas D; Culurgioni F; Tandurella I; Latte G; Palmas A; Angelucci E
Hematol Oncol; 2016 Mar; 34(1):17-21. PubMed ID: 25626861
[TBL] [Abstract][Full Text] [Related]
16. Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.
Baronciani D; Rambaldi A; Iori AP; Di Bartolomeo P; Pilo F; Pettinau M; Depau C; Mico C; Santarone S; Angelucci E
Am J Hematol; 2008 Sep; 83(9):717-20. PubMed ID: 18626885
[TBL] [Abstract][Full Text] [Related]
17. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
18. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
19. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
